Pooja, Ashok Prabhu K, Durga Rao Y, Sowndarya K, Nandini M
Pooja1, Ashok Prabhu K2, Durga Rao Y1, Sowndarya K1, Nandini M1*
1Department of Biochemistry, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, Karnataka, India – 575004.
2Department of Clinical Biochemistry, Kasturba Medical College Hospital, Ambedkar Circle, Mangalore, Karnataka, India -575001.
Volume - 15,
Issue - 9,
Year - 2022
Mortality due to atherosclerosis is very common and the oxidative modification of low-density lipoprotein (LDL) is responsible for the progression of atherosclerosis. Estimation of oxidized LDL (Ox-LDL), myeloperoxidase (MPO), and paraoxonase (PON1) in subjects with elevated LDL and correlation of oxidized LDL with MPO and PON1 was the main objective. Ox-LDL was determined by ELISA. Activity of Myeloperoxidase and Paraoxonase was estimated by spectrophotometric method. LDL and HDL estimations were carried out in the autoanalyser. Significant increase in the myeloperoxidase and Ox-LDL with the significant decrease in the paraoxonase levels were obseved (p<0.001). No significant change in the HDL levels was seen. LDL showed a positive association with MPO and a negative association with Basal Paraoxonase (BPON) in both cases and controls. Ox-LDL also showed a positive association with MPO and a negative association with BPON only in cases, while no significant association was seen in controls. Ox-LDL seems to be a more sensitive indicator of cardiovascular disease risk than either HDL or LDL cholesterol. Measurement of Ox-LDL, /Myeloperoxidase and Paraoxonase may provide additional details in cardiovascular disease risk prediction.
Cite this article:
Pooja, Ashok Prabhu K, Durga Rao Y, Sowndarya K, Nandini M. Correlation of Oxidised LDL with Oxidant and Antioxidant enzymes in subjects with Elevated LDL levels. Research Journal of Pharmacy and Technology. 2022; 15(9):3836-0. doi: 10.52711/0974-360X.2022.00643
Pooja, Ashok Prabhu K, Durga Rao Y, Sowndarya K, Nandini M. Correlation of Oxidised LDL with Oxidant and Antioxidant enzymes in subjects with Elevated LDL levels. Research Journal of Pharmacy and Technology. 2022; 15(9):3836-0. doi: 10.52711/0974-360X.2022.00643 Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-9-3
1. Prabha JL, Sankari M. Role of Il-1 in Atherosclerosis. Research J. Pharm. and Tech 2018; 11(7): 3163-3166.
2. Kattoor AJ, Kanuri SH, Mehta JL. Role of Ox-LDL and LOX-1 in Atherogenesis. Curr Med Chem 2019;26(9):1693-1700.
3. Khosravi M, Poursaleh A, Ghasempour G, Farhad S, Najafi M. The effects of oxidative stress on the development of atherosclerosis. Biol Chem 2019;400(6):711-732.
4. Ndanusa AH, Rohini K, Uma SA, Khin MA. Effect of Zingiber officinale on Lipid profile of Sprague-Dawley rats induced with Streptozotocin. Research J. Pharm. and Tech. 2020; 13(8):3577-3579.
5. Dayuan Li, Jawahar Mehta L. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect against oxidized low density lipoprotein induced endothelial dysfunction. Endothelium Journal of endothelial Cell Research 2003; 10: 17– 21.
6. Deakin S, Bioletto S, Bochaton-Piallat M, James R. HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. Free Radical Biology and Medicine 2011; 50: 102- 109.
7. Suematsu Y, Goto M, Park C, Nunes ACF, Jing W, Streja E,et al. Association of Serum Paraoxonase/Arylesterase Activity With All-Cause Mortality in Maintenance Hemodialysis Patients. J Clin Endocrinol Metab 2019 Oct 1;104(10):4848-4856.
8. Ferretti G, Bacchetti T, Campanati A, Simonetti O, Liberati G, Offidani A. Correlation between lipoprotein(a) and lipid peroxidation in psoriasis: role of the enzyme paraoxonase-1. Br J Dermatol 2012;166(1):204-207.
9. Rosenblat M, L Gaidukov, O Khersonsky et al. The catalytic histidine dyad of high density Lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem 2006; 281:7657– 7665.
10. Boshtam M, Razavi A. E, Pourfarzam M , Ani M, Naderi GA, Basati G et al .Serum paraoxonase 1 activity is associated with fatty acid composition of high density lipoprotein. Disease Markers .2013; 35: 273–280.
11. A Gugliucci, M Numaguchi, R Caccavello, S Kimura. Paraoxonase1 lactonase activity and distribution in the HDL subclasses in the cord blood. Redox Report 2014; 19: 124–132.
12. Aviram M, Rosenblat M, Bisgaier C, Newton R, Primo-Parmo S, La Du BN et al. Paraoxonase inhibits high- density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. Journal of Clinical Investigation 1998; 101:1581-90.
13. Basati G, Emami Razavi A, Abdi S, Sarrafzadegan N. Association between adipokine and myeloperoxidase levels in patients with coronary artery disease. Acta Med Iran 2015;53(1):25-29.
14. Shih DM, Gu L, Hama S, Xia YR, Navab M, Fogelman AM etal . Genetic dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996; 97:1630-1639.
15. Nahrendorf M, Sosnovik D, Chen J, Panizzi P, Figueiredo J, Aikawa E et al. Activatable Magnetic Resonance Imaging Agent Reports Myeloperoxidase Activity in Healing Infarcts and Noninvasively Detects the Anti- inflammatory Effects of Atorvastatin on Ischemia- Reperfusion Injury. Circulation 2008; 117: 1153-1160.
16. Kacprzak M, Zielinska M. Prognostic value of myeloperoxidase concentration in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Int J Cardiol 2016;223: 452-457.
17. Rudolph V, Andrie RP, Rudolph TK, Friedrichs K, Klinke A et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med 2010; 16: 470–474.
18. Reynolds WF, Rhees J, Maciejewski D, Paladino T, Sieburg H, et al. Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer’s disease. Exp Neurol 1999; 155: 31–41.
19. Malle E, Marsche G, Arnhold J, Davies M. Modification of low-density lipoprotein by Myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochimica Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2006; 1761: 392-415.
20. Schindhelm R, van der Zwan L, Teerlink T, Scheffer P. Myeloperoxidase:A Useful Biomarker for Cardiovascular Disease Risk Stratification?Clinical Chemistry 2009; 55: 1462-1470.
21. Suguichi H, Uji Y, Okabe H, Irie T, Uekama K, Kayahara N etal. Direct measurement of HDL cholesterol in serum with polyethylene glycol- modified enzymes and sulfated α-Cyclodextrin. Clin Chem 1995; 41: 717-723.
22. Matsuzaki Y, Kawaguchi E, Morita Y, Mashige F, Ohisa S, Nakahara K, et al. Evaluation of two kinds of reagents for direct determination of HDL–cholesterol.J Anal Bio-Sc 1996; 19: 419-427.
23. Pisani T, Gebski CP, Leary ET, Warnock GR, Ollington JF. Accurate direct determination of low- density lipoprotein cholesterol using an immune separation reagent and enzymatic cholesterol assay. Arch Pathol Lab Med 1995; 119: 1127- 1135.
24. Alamdari DH, Kostidou E, Paletas K, Sarigianni M, Konstas AG, Karapiperidou A, Koliakos G. High sensitivity enzyme-linked immunosorbent assay (ELISA) method for measuring protein carbonyl in samples with low amounts of protein. Free Radic Biol Med 2005; 39:1362-7.
25. Souparnika S. Emerging Role of Myeloperoxidase in the Prognosis of Nephrotic Syndrome in Patients Before and After Steroid Therapy.Journal of clinical and diagnostic research 2015; 9: 1-4.
26. Bełtowski J e. Species- and substrate-specific stimulation of human plasma paraoxonase 1 (PON1) activity by high chloride concentration. Acta Biochim Pol 2002; 49: 927-936.
27. Sigurdardottir V, Fagerberg B, Hulthe J. Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-years-old men (AIR study). J Intern Med 2002; 252: 440–447
28. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R etal . Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001; 21: 844–848.
29. Kondo A, Muranaka Y, Ohta I, Notsu K, Manabe M, Kotani K et al .Relationship between triglyceride concentrations and LDL size evaluated by Malondialdehyde- modified LDL . Clin Chem 2001; 47: 893–900.
30. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low density lipoprotein .FEBS Lett 1991; 286: 152-154.
31. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH: Distribution of paraoxon hydrolytic activity of patients after myocardial infarction. Clin Chem 1986; 32:671-673.
32. Idrees M, Siddiq AR, Ajmal M, Akram M, Khalid RR, Hussain A, et al. Decreased serum PON1 arylesterase activity in familial hypercholesterolemia patients with a mutated LDLR gene. Genet Mol Biol 2018;41(3):570-577.
33. Miljkovic M, Stefanovic A, Vekic J, Zeljkovic A, Gojkovic T, Simic-Ogrizovic S, Bogavac-Stanojevic N, Cerne D, Ilic J, Stefanovic I, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, Kotur-Stevuljevic J. Activity of paraoxonase 1 (PON1) on HDL2 and HDL3 subclasses in renal disease. Clin Biochem 2018 Sep;60:52-58.
34. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Durrington PN et al .Paraoxonase status in coronary heart disease.: are activity and concentration more important than genotype? Arterioscler Thromb Vasc.Biol 2001; 21: 1451 -1457.
35. Basati G, Emami Razavi A, Abdi S, Sarrafzadegan N. Association between adipokine and myeloperoxidase levels in patients with coronary artery disease. Acta Med Iran 2015;53(1):25-29.
36. Heslop CL, Frohlich JJ, Hill JS. Myeloperoxidase and C-reactive protein have combined utility for long-term prediction of cardiovascular mortality after coronary angiography.Journal of the American College of Cardiology 2010; 55: 1102–1109.